香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部份內容而產生或因倚賴 該等內容而引致的任何損失承擔任何責任。 WUXI APPTEC CO., LTD. * 無錫藥明康德新藥開發股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2359） 有關出售附屬公司完成交割 的業務發展最新情況 茲提述無錫藥明康德新藥開發股份有限公司（「本公司」）日期為2025年10月24日 的公告（「該公告」），內容有關上海藥明出售而高瓴購買康德弘翼及津石醫藥 的所有股份。除非文意另有所指，否則本公告所用詞彙與該公告所定義詞彙具 有相同涵義。 截至本公告日期，上海藥明已收到高瓴按股權轉讓協議約定足額支付的第一 期轉讓對價人民幣15.4億元，股權轉讓協議約定的交割先決條件已滿足，本次 交易已完成交割，康德弘翼及津石醫藥不再納入本公司合併報表範圍。康德弘 翼及津石醫藥及其他相關各方將按股權轉讓協定約定辦理本次交易涉及康德 弘翼及津石醫藥的股權變更登記手續，並預計在2025年12月31日之前完成變更 登記。 經本公司財務部門按中 ...

Core Viewpoint - WuXi AppTec announced the completion of a transaction involving the sale of 100% equity in two subsidiaries for a total consideration of 2.8 billion yuan, which is expected to generate a net profit of approximately 960 million yuan, representing over 10% of the company's audited net profit for the fiscal year 2024 [1] Group 1 - The company’s wholly-owned subsidiary, Shanghai WuXi AppTec New Drug Development Co., Ltd., transferred its holdings in Shanghai Kangde Hongyi Medical Clinical Research Co., Ltd. and Shanghai WuXi Jinshi Pharmaceutical Technology Co., Ltd. [1] - The first payment of 1.54 billion yuan has been received from the acquirers, and the transaction has been completed with the target companies no longer included in the company’s consolidated financial statements [1] - The transaction is subject to the fulfillment of various agreements outlined in the equity transfer agreement by all parties involved [1]

证券代码：603259 证券简称：药明康德 公告编号：临2025-073 无锡药明康德新药开发股份有限公司 关于出售资产进展公告 二、交易进展 截至本公告日，转让方已收到受让方按《股权转让协议》约定足额支付的第 一期股权转让价款人民币 15.4 亿元，《股权转让协议》约定的交割先决条件已 满足，本次交易已完成交割，目标公司不再纳入公司合并报表范围。目标公司及 相关各方将按《股权转让协议》约定办理本次交易涉及的目标公司的市监局变更 登记手续，预计 2025 年 12 月 31 日之前完成变更登记。 经公司财务部门按中国企业会计准则初步核算，截至本公告日本次交易预计 产生税后净利润约 9.6 亿元，占公司最近一期（2024 年度）经审计归母股东净利 润的比例超过 10%。公司将根据中国企业会计准则与国际财务报告准则等有关需 适用的规定对投资收益进行会计处理，具体影响金额以注册会计师年度审计确认 后的结果为准。后续各方仍需继续履行《股权转让协议》项下的各项约定。敬请 投资者注意投资风险。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任 ...

Group 1 - BlackRock's long position in Wuxi AppTec Co., Ltd. H-shares decreased from 5.24% to 4.57% as of December 9, 2025 [1]

Core Viewpoint - WuXi AppTec announced the completion of the equity transfer of its subsidiary, with an initial payment of 1.54 billion yuan, resulting in a significant impact on the company's financials [1] Group 1: Transaction Details - The equity transfer agreement has been fulfilled, and the transaction has been completed, leading to the target company being excluded from the consolidated financial statements of WuXi AppTec [1] - The expected after-tax net profit from this transaction is approximately 960 million yuan, which represents over 10% of the company's latest audited net profit attributable to shareholders for the fiscal year 2024 [1] Group 2: Future Actions - The target company and related parties will proceed with the registration changes as stipulated in the agreement, with an expected completion date before December 31, 2025 [1]

Core Insights - The article highlights the top and bottom AH share premium rates as of December 15, with Northeast Electric (00042) leading at a premium of 900.00% and CATL (03750) at the bottom with a premium of -11.03% [1][2][3] Premium Rate Rankings - The top three AH stocks by premium rate are: - Northeast Electric (00042) with a premium of 900.00% and a deviation value of 26.91% [1][2] - Beijing Capital Machinery (00187) with a premium of 266.67% and a deviation value of 27.25% [1][2] - Hongye Futures (03678) with a premium of 265.78% and a deviation value of -3.92% [1][2] - The bottom three AH stocks by premium rate are: - CATL (03750) with a premium of -11.03% and a deviation value of -2.28% [1][3] - China Merchants Bank (03968) with a premium of -0.77% and a deviation value of -0.05% [1][3] - Heng Rui Medicine (01276) with a premium of 1.62% and a deviation value of -1.73% [1][3] Deviation Value Rankings - The top three AH stocks by deviation value are: - Beijing Capital Machinery (00187) with a deviation value of 27.25% [1][4] - Northeast Electric (00042) with a deviation value of 26.91% [1][4] - Hongxing Meikailong (01528) with a deviation value of 18.57% [1][4] - The bottom three AH stocks by deviation value are: - GAC Group (02238) with a deviation value of -19.95% [1][5] - First Tractor Company (00038) with a deviation value of -16.78% [1][5] - Longyuan Power (00916) with a deviation value of -13.18% [1][5]

Investment Rating - The report maintains a positive outlook on the pharmaceutical industry, recommending a focus on innovative drugs and sectors with improving performance, such as medical devices and upstream segments [3][4]. Core Insights - The pharmaceutical sector experienced a decline of 1.0% this week, ranking 17th among 31 sub-industries. The overall valuation of the pharmaceutical sector stands at 29.2 times earnings, placing it 10th among the primary industries [2][4][7]. - Key events include Fosun Pharma granting exclusive global rights for its oral GLP-1 drug to Pfizer, with potential total payments reaching $2.085 billion. Additionally, Eli Lilly's GLP-1/GIP/GCGR agonist Retatrutide showed promising Phase III clinical data, achieving a weight loss of 28.7% over 68 weeks [3][14][17]. - The report highlights significant mergers and acquisitions, such as Sobi's acquisition of Arthrosi for $950 million upfront and $550 million in milestone payments, and Zhaoli Pharmaceutical's planned acquisition of a multi-trace element injection asset group for approximately RMB 356 million [3][15][22]. Market Performance - The pharmaceutical index decreased by 1.0% this week, while the Shanghai Composite Index fell by 0.3%. The overall performance of the pharmaceutical sector was ranked 17th among 31 sub-industries [2][4][6]. - The report details the performance of various sub-sectors, with notable declines in medical circulation (-4.2%), offline pharmacies (-4.3%), and blood products (-4.1%), while medical R&D outsourcing saw an increase of 3.7% [7][11]. Recent Key Events - The report discusses recent business developments, including the approval of Shanghai Pharma's new drug, and the change of control at Tailong Pharmaceutical, which will now be under Jiang Pharmaceutical Holdings [20][22]. - It also notes the IPO application of Shiyao Innovation, which was accepted with a market value of RMB 47.9 billion, focusing on health-related sectors and innovative drugs [23]. Company Valuation - The report provides a valuation table for key companies in the pharmaceutical sector, indicating projected earnings per share (EPS) and price-to-earnings (PE) ratios for 2025 to 2027. For instance, Mindray Medical is projected to have a PE of 23 in 2025, while Hengrui Medicine is expected to have a PE of 48 [29].

Core Insights - The pharmaceutical industry is experiencing a surge in innovative products, with clear domestic demand and significant potential for international expansion [4][14][25] - Investment opportunities are concentrated in innovative drugs and their supply chains, with a notable performance from CRO/CMO and chemical pharmaceuticals [9][15][17] - The report emphasizes the importance of innovation as the primary solution to industry challenges, driven by stable demand and supportive policies [26][32][41] Industry Overview - The pharmaceutical sector has faced revenue declines, with a 0.9% year-on-year decrease in revenue for the first three quarters of 2025, and net profit down by 2.2% [15][16] - The innovative drug sector has outperformed, with CRO/CMO and chemical pharmaceuticals showing net profit growth of 31.0% and 16.6% respectively [17][18] - The overall market is characterized by low fund holdings and historical valuation bottoms, indicating high investment value [20][25] Demand and Payment Dynamics - The demand for healthcare services is steadily increasing, with a projected 5% growth in total medical visits and hospital admissions in 2024 [26][28] - The aging population is expected to drive long-term demand, with 220 million people aged 65 and above by 2050 [28][30] - The medical insurance fund's income growth has outpaced expenditure growth, leading to a significant increase in fund reserves [32][36] Financing and Market Trends - The IPO market for healthcare has rebounded, with 28 IPOs in the first three quarters of 2025, a 100% increase from the previous year [42][43] - License-out transactions have surged, with transaction numbers increasing by 41% and total amounts reaching $92 billion, indicating a robust market for innovative drug licensing [48][50] - The number of IND applications and new clinical trials for innovative drugs has been steadily increasing, with a notable rise in NDA approvals [53][57] Technological Advancements - The report highlights the emergence of new technologies such as ADC and small nucleic acids, with domestic companies leading in these areas [60] - The focus on dual antibodies and GLP-1 drugs is expected to drive significant growth, with multiple development directions emerging [9][60] - The report notes that domestic companies are increasingly recognized for their innovative capabilities, particularly in the ADC space [60]

Core Viewpoint - WuXi AppTec experienced significant trading activity on December 12, with a total of 201,800 shares traded through block transactions, amounting to 18.9793 million yuan, all at a price of 94.05 yuan per share [1] Group 1: Trading Activity - On December 12, four block trades were executed for WuXi AppTec, with a total trading volume of 201,800 shares and a total transaction value of 18.9793 million yuan [1] - The trading price for all transactions was consistent at 94.05 yuan, with institutional proprietary seats involved in both buying and selling, resulting in a net sell of 18.9793 million yuan [1] Group 2: Recent Trading Statistics - Over the past three months, WuXi AppTec has recorded a total of seven block trades, with a cumulative transaction value of 35.1573 million yuan [2] - The closing price for WuXi AppTec on the same day was 94.05 yuan, reflecting a 0.70% increase, with a daily turnover rate of 1.91% and a total trading volume of 4.424 billion yuan [2] - The stock has seen a net outflow of 544 million yuan in principal funds for the day, while over the past five days, it has increased by 4.04% with a total net inflow of 340 million yuan [2] Group 3: Margin Trading Data - The latest margin financing balance for WuXi AppTec stands at 7.237 billion yuan, having decreased by 301 million yuan over the past five days, representing a decline of 3.99% [2]

| 交易日期 | 证券間称 | 证券代码 | | 成交价(元) 成交金额(万元) 成交量(*) 买入营业部 | | 类出营业部 | 是否为专场 | | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 852.66 | 9.07 9.07 12 10.6 | 机构专用 | 彩 | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 380.33 | 4.04 有限公司总部 | 机构专用 | Ka | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 380,33 | 4.04 有限公司总盘 | 机构专用 | 188 | | 2025-12-12 | 药明康德 | 603259 | 94.05 | 284.61 | 3.03 有限公司总营 | 机构专用 | Ka | 12月12日，药明康德大宗交易成交20.18万股，成交额1897.93万元，占当日总成交额的0.43%，成交价 94.05元，较市场收盘价94.05元持平。 ...